U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H18I6N2O9
Molecular Weight 1215.8131
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IOTROXIC ACID

SMILES

OC(=O)C1=C(I)C=C(I)C(NC(=O)COCCOCCOCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C1I

InChI

InChIKey=JXMIBUGMYLQZGO-UHFFFAOYSA-N
InChI=1S/C22H18I6N2O9/c23-9-5-11(25)19(17(27)15(9)21(33)34)29-13(31)7-38-3-1-37-2-4-39-8-14(32)30-20-12(26)6-10(24)16(18(20)28)22(35)36/h5-6H,1-4,7-8H2,(H,29,31)(H,30,32)(H,33,34)(H,35,36)

HIDE SMILES / InChI

Molecular Formula C22H18I6N2O9
Molecular Weight 1215.8131
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Iotroxic acid (INN), also known as meglumine iotroxate (BAN) (Biliscopin) for infusion is indicated for radiological examination of the hepatic and biliary ducts and gallbladder when examination by oral technique is unsuccessful or inappropriate. Following intravenous administration Biliscopin is rapidly excreted, mainly by the liver into the bile. Visualisation of the hepatic and common bile ducts and the gallbladder can, therefore, be achieved. Visualisation of the biliary ducts is usually possible 30-60 minutes after completion of administration. In vitro meglumine iotroxate binds to plasma proteins to the extent of 60-90% depending on concentration. In animals it crosses the placental barrier. This agent is the single intravenous cholangiographic agent, which is currently available in Australia.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Biliscopin

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Pharmacology of iotroxic acid, a new intravenous cholangiographic agent. II. Experimental animal study of side effects].
1978
Patents

Sample Use Guides

One bottle (100 mL) for infusion (1 mL=20 drops)
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:37:16 GMT 2023
Edited
by admin
on Fri Dec 15 16:37:16 GMT 2023
Record UNII
84C5PTP9X6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IOTROXIC ACID
INN   JAN   MART.   USAN   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
3,3'-(3,6,9-TRIOXAUNDECANEDIOYLDIAMINO)BIS(2,4,6-TRIIODOBENZOIC ACID)
Common Name English
BILISCOPIN
Brand Name English
IOTROXIC ACID [USAN]
Common Name English
SH-213 AB
Code English
IOTROXIC ACID [JAN]
Common Name English
iotroxic acid [INN]
Common Name English
SH-213AB
Code English
3,3'-(OXYBIS(ETHYLENEOXYMETHYLENECARBONYLIMINO))BIS(2,4,6-TRIIODOBENZOIC ACID)
Common Name English
BENZOIC ACID, 3,3'-(OXYBIS(2,1-ETHANEDIYLOXY(1-OXO-2,1-ETHANEDIYL)IMINO))BIS(2,4,6, TRIIODO-
Common Name English
SH 213 AB
Code English
IOTROXIC ACID [WHO-IP]
Common Name English
IOTROXIC ACID [MART.]
Common Name English
ACIDUM IOTROXICUM [WHO-IP LATIN]
Common Name English
Iotroxic acid [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C28500
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
WHO-VATC QV08AC02
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
WHO-ATC V08AC02
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
Code System Code Type Description
WIKIPEDIA
Iotroxic acid
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
ChEMBL
CHEMBL1651905
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
PUBCHEM
3740
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
SMS_ID
100000083115
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
FDA UNII
84C5PTP9X6
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
INN
3652
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
EVMPD
SUB08261MIG
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
CAS
51022-74-3
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
DRUG BANK
DB08945
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
NCI_THESAURUS
C72080
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
DRUG CENTRAL
3991
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID3048782
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
IOTROXIC ACID
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY Description: An almost white powder. Solubility: Practically insoluble in water, benzene R, and ether R; freely soluble in methanol R and dimethylformamide R; dissolves in solutions of alkali hydroxides. Category: Used in the preparation of meglumine iotroxate as a radiocontrast medium. Storage: Iotroxic acid should be kept in a well-closed container, protected from light. Requirements: Iotroxic acid contains not less than 98.0% and not more than the equivalent of 102.0% of C22H18I6N2O9, calculated with reference to the anhydrous substance.
ECHA (EC/EINECS)
256-917-3
Created by admin on Fri Dec 15 16:37:16 GMT 2023 , Edited by admin on Fri Dec 15 16:37:16 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY